Site-specific GlcNAcylation of Human Erythrocyte Proteins: Potential Biomarker(s) for Diabetes
Overview
Authors
Affiliations
Objective: O-linked N-acetylglucosamine (O-GlcNAc) is upregulated in diabetic tissues and plays a role in insulin resistance and glucose toxicity. Here, we investigated the extent of GlcNAcylation on human erythrocyte proteins and compared site-specific GlcNAcylation on erythrocyte proteins from diabetic and normal individuals.
Research Design And Methods: GlcNAcylated erythrocyte proteins or GlcNAcylated peptides were tagged and selectively enriched by a chemoenzymatic approach and identified by mass spectrometry. The enrichment approach was combined with solid-phase chemical derivatization and isotopic labeling to detect O-GlcNAc modification sites and to compare site-specific O-GlcNAc occupancy levels between normal and diabetic erythrocyte proteins.
Results: The enzymes that catalyze the cycling (addition and removal) of O-GlcNAc were detected in human erythrocytes. Twenty-five GlcNAcylated erythrocyte proteins were identified. Protein expression levels were compared between diabetic and normal erythrocytes. Thirty-five O-GlcNAc sites were reproducibly identified, and their site-specific O-GlcNAc occupancy ratios were calculated.
Conclusions: GlcNAcylation is differentially regulated at individual sites on erythrocyte proteins in response to glycemic status. These data suggest not only that site-specific O-GlcNAc levels reflect the glycemic status of an individual but also that O-GlcNAc site occupancy on erythrocyte proteins may be eventually useful as a diagnostic tool for the early detection of diabetes.
Interplay Between Metabolic Pathways and Increased Oxidative Stress in Human Red Blood Cells.
Spinelli S, Marino A, Morabito R, Remigante A Cells. 2024; 13(23).
PMID: 39682773 PMC: 11640724. DOI: 10.3390/cells13232026.
The post-translational modification O-GlcNAc is a sensor and regulator of metabolism.
Morales M, Pratt M Open Biol. 2024; 14(10):240209.
PMID: 39474868 PMC: 11523104. DOI: 10.1098/rsob.240209.
Chapman J Mol Cell Proteomics. 2024; 23(12):100866.
PMID: 39442692 PMC: 11696785. DOI: 10.1016/j.mcpro.2024.100866.
Hassanzadeh K, Liu J, Maddila S, Mouradian M Pharmacol Rev. 2024; 76(6):1254-1290.
PMID: 39164116 PMC: 11549938. DOI: 10.1124/pharmrev.123.001111.
Hu J, Xia W, Zeng S, Lim Y, Tao Y, Sun Y Nat Commun. 2024; 15(1):2677.
PMID: 38538591 PMC: 10973503. DOI: 10.1038/s41467-024-46898-1.